Regarding AST and ALT reductions, when sensitivity analyses were performed on studies which included only patients with biopsy-proven NASH, the significant results were only seen in synbiotics and probiotics. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.